Clinical chemistry

Sapreme Appoints CEO, BoD Chair and SAB to Advance Development of Next-Generation RNA Therapeutics for Genetically Driven Diseases

Retrieved on: 
Dienstag, Mai 28, 2024
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, MSD, Medical laboratory, University College Dublin, Self-publishing, Whitehead Institute, Drug development, Molecular medicine, Vaccine, Genetics, RNA, Therapy, Infection, ALS, Free University, Saponin, MIT, MD, MB, Organon, Master of Science, Clinical chemistry, LUMC, Protein, Asos, Duchenne muscular dystrophy, Medicinal chemistry, Psychiatry, Neurology, Complex conjugate, EAN, SAB, Peptide, Damme, Patient, Doctor of Philosophy, Organization, Free University of Berlin, University, Schering-Plough, Leiden University, DMD, Growth, Spacecraft, Cancer, Leiden University Medical Center, Pharmaceutical industry

Sapreme , a biotechnology company focused on developing next-generation RNA therapeutics for patients with genetically driven diseases, today announced the appointment of Marco Timmers, PhD, as Chief Executive Officer and Jeanne Bolger, MD, to Chair of the Sapreme Board of Directors (BoD).

Key Points: 
  • Sapreme , a biotechnology company focused on developing next-generation RNA therapeutics for patients with genetically driven diseases, today announced the appointment of Marco Timmers, PhD, as Chief Executive Officer and Jeanne Bolger, MD, to Chair of the Sapreme Board of Directors (BoD).
  • Before joining Sapreme, he was CEO of Byondis (formerly Synthon Biopharmaceuticals), a clinical-stage biopharmaceutical company developing Antibody-Drug Conjugates (ADCs) targeting intractable cancers and auto-immune diseases.
  • During his time at Byondis, Dr. Timmers also served as Chief Scientific Officer, guiding the company’s clinical strategies and growth.
  • I look forward to working with the team at Sapreme to further advance this innovative platform and accelerate our pipeline of RNA therapeutic candidates addressing a range of genetically driven diseases,” said Marco Timmers, Chief Executive Officer of Sapreme.

New research confirms that Beethoven had lead poisoning -- but it didn't kill him

Retrieved on: 
Montag, Mai 6, 2024
Hearing loss, Death, Medical laboratory, Clinical chemistry, Doctor of Philosophy, AACC, Rifaʽi, Diagnosis, Bermann, Liver, Physician, Harvard Medical School, Genome, Mass spectrometry

WASHINGTON, May 6, 2024 /PRNewswire/ -- To this day, no one knows for certain what caused the liver and kidney disease that led to Ludwig van Beethoven's untimely death. However, a new letter to the editor in the Association for Diagnostics & Laboratory Medicine's (ADLM's, formerly AACC's) journal Clinical Chemistry rules out one popular theory, showing that the composer was exposed to lead levels that were high — but not high enough to kill him.

Key Points: 
  • High lead levels are commonly associated with all of these conditions — and are also associated with other traits of Beethoven's, such as his infamous temper, memory lapses, and chronic clumsiness.
  • However, further studies eventually found that that lock of hair belonged to a woman, not Beethoven.
  • Rifai's group analyzed the locks for lead using two different versions of a highly accurate testing technique known as mass spectrometry.
  • From this, the researchers were able to estimate that Beethoven's blood lead concentration would have been 69 to 71 µg/dL.

Europe Medical Diagnostics Market Insights Report 2024-2028 with Competitive Analysis of Labcorp, Quest Diagnostics, Sonic Healthcare, Eurofins Scientific, Synlab and Medicover - ResearchAndMarkets.com

Retrieved on: 
Freitag, März 8, 2024
Medical Devices, Health, Pandemic, Coagulation, POC, Sonic Healthcare, Growth, Immunoassay, Government, Urbanization, Clinical chemistry, Eurofins Scientific, Attention, COVID-19, Quest Diagnostics, Hematology, Medicine, Infection, Diagnosis, Labcorp, IVD, Medical device

The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Europe Medical Diagnostics Market (Immunoassays, Clinical Chemistry, Haematology & Coagulation): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
  • European medical diagnostics market is expected to reach US$109.91 billion in 2028, growing at a CAGR of 5.69%, for the time period of 2024-2028.
  • The report provides a comprehensive analysis of the European Medical Diagnostics Market.
  • The company profiles of leading players (Labcorp, Quest Diagnostics, Sonic Healthcare, Eurofins Scientific, Synlab and Medicover) are also presented in detail.

The World Market for Veterinary Diagnostics, 7th Edition - ResearchAndMarkets.com

Retrieved on: 
Dienstag, Februar 6, 2024
Veterinary, Health, Seventh Edition, Row, PRRS, Infection, Betaarterivirus suid 1, BVD, Clinical chemistry, Bovine viral diarrhea, Animal, IVD, Classical swine fever, TGE, Pet, Vaccine

The "World Market for Veterinary Diagnostics, 7th Edition" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "World Market for Veterinary Diagnostics, 7th Edition" report has been added to ResearchAndMarkets.com's offering.
  • Despite various challenges, the veterinary diagnostics market has shown consistent growth and is forecasted to continue on this trajectory.
  • The World Market for Veterinary Diagnostics, 7th Edition meticulously examines the global veterinary diagnostics market, focusing on two key components: companion animal (pets) diagnostics and food animal diagnostics.
  • The report provides a comprehensive analysis of major veterinary disease markets, offering insights into overall market performance and development.

Lapatinib Increases Overall Survival in Metastatic Breast Cancer Patients With HER2-Positive Circulating Tumor Cells

Retrieved on: 
Donnerstag, Januar 4, 2024
Diagnosis, Clinical chemistry, Patient, Chinese, Lapatinib, Biology, Medical laboratory, AACC, Cancer, Medical imaging

WASHINGTON, Jan. 4, 2024 /PRNewswire/ -- A new study shows that lapatinib, a drug used for the treatment of metastatic HER2-positive cancer, is associated with improved overall survival in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells (CTCs). This groundbreaking finding was published today in a special issue of the Association for Diagnostics & Laboratory Medicine's (formerly AACC's) Clinical Chemistry journal titled "Cancer: Biology & Diagnostics."

Key Points: 
  • Findings published in the special "Cancer: Biology & Diagnostics" issue of ADLM's Clinical Chemistry journal
    WASHINGTON, Jan. 4, 2024 /PRNewswire/ -- A new study shows that lapatinib, a drug used for the treatment of metastatic HER2-positive cancer, is associated with improved overall survival in patients with initially HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells (CTCs).
  • This groundbreaking finding was published today in a special issue of the Association for Diagnostics & Laboratory Medicine's (formerly AACC's) Clinical Chemistry journal titled "Cancer: Biology & Diagnostics."
  • View the full study here: https://doi.org/10.1093/clinchem/hvad144

GLUCOTRACK ANNOUNCES SHAREHOLDER UPDATE

Retrieved on: 
Montag, November 13, 2023
Diet, Longevity, Insulin, Hypoglycemia, American Diabetes Association, Diagnosis, CGM, Insurance, Trust, CMS, Evidence, Diabetes, Growth, Doctor of Philosophy, Medicare, Himawari (satellites), Prediabetes, Clinical chemistry, Letter, BGM, Environment, Management, Medical device, Pharmaceutical industry

Rutherford, NJ, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a shareholder update letter.

Key Points: 
  • Rutherford, NJ, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that Paul V. Goode, PhD, President and Chief Executive Officer has provided a shareholder update letter.
  • In recent years, the diabetes market has experienced a significant transformation, driven by the growth of continuous glucose monitoring (CGM).
  • This was the first update to the guidelines since 2011 and included major shifts in clinical thinking.
  • In the last shareholder update, we had recognized that this would raise the regulatory bar for any non-invasive glucose sensor performance.

Trinity Biotech Announces Q2 2023 Financial Results

Retrieved on: 
Dienstag, Oktober 3, 2023
KPI, Clinical chemistry, Federal Food, Drug, and Cosmetic Act, Partnership, Q3, SG, HIV, Diagnosis of HIV/AIDS, Reference, Balance sheet, Ion exchange, U.S. FDA, Mayo Clinic Center for Innovation, Ministry, A1C, EBITDA, Traction, Autoimmune disease, Supply chain, Investment, World Health Organization, Ministry of Health (Kuwait), Units of paper quantity, Growth, FDA, Calibration, Glycated hemoglobin, Pharmaceutical industry, Beauty salon, Fine chemical, Retail, Medical device, Video game, Vaccine, Renewable energy, Creative industries, Bank, Quest, Q2, Finance, Health, Sjögren syndrome, Diabetes

DUBLIN, Ireland, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended June 30, 2023.

Key Points: 
  • DUBLIN, Ireland, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended June 30, 2023.
  • Total revenue for fiscal Q2, 2023 was $13.9m (excluding Fitzgerald Industries, which was disposed of in April 2023).
  • In August, Trinity Biotech received U.S. FDA 510(k) clearance for the Premier Resolution System, the automated analyzer for accurate & precise quantification of haemoglobin variants.
  • Total revenues for Q2, 2023 were $13.9m which compares to $15.4m in Q2, 2022, a decrease of 9.8% and which were broken down as follows:

QuidelOrtho Ranks No. 1 in Customer Satisfaction for Six Years in a Row

Retrieved on: 
Dienstag, Juli 25, 2023
Health, Biotechnology, Clinical chemistry, Partnership, QuidelOrtho, Engineering, Culture, Chemistry, Nursing

#1 in Clinical Chemistry in:

Key Points: 
  • #1 in Clinical Chemistry in:
    “For six straight years, our customers have rated QuidelOrtho #1 for overall customer satisfaction in the U.S. diagnostics market based on real-world system and service performance under some of the most challenging conditions in modern history,” said Douglas Bryant, President and Chief Executive Officer of QuidelOrtho.
  • Superior partnership and support are more important than ever as labs experience greater demand for more complex testing, challenging budgets and a workforce shifting from more specialists to more generalists.
  • With QuidelOrtho solutions, labs get the partnership they need, along with next-level data services to continually improve the speed and quality of care.
  • “It’s the people who deliver the award-winning partnership and support that labs depend on,” said Karen Taylor, vice president of QuidelOrtho’s global customer experience and services organization.

Global Next-Generation Diagnostics Market Trends & Growth Projections to 2028 - ResearchAndMarkets.com

Retrieved on: 
Freitag, Juli 21, 2023
Science, Health, Clinical Trials, Research, Universe, Clinical chemistry, COVID-19, Liquid biopsy, Molecular diagnostics, Infection, Genomics, POCT, Traction, GDP, Patient, Laboratory, Physician, Strategy, Mergers and acquisitions, IVD, Growth, AI, Multisystem inflammatory syndrome in children, Environment, Automation, Medical device, Retail, Marketing, Immunoassay

As COVID-19 transitions to the endemic phase, automation solutions and smart, connected laboratories will catalyze recovery in the next-generation diagnostics industry.

Key Points: 
  • As COVID-19 transitions to the endemic phase, automation solutions and smart, connected laboratories will catalyze recovery in the next-generation diagnostics industry.
  • The study examines next-generation diagnostics market trends and growth projections to 2028 across different geographical regions, innovative in vitro diagnostics technologies and applications, major vendors to watch, and growth opportunities in the post-pandemic future.
  • The report on next-generation diagnostics industry covers a range of key topics, providing insights into growth opportunities, revenue trends, mergers and acquisitions, predictions for 2023, and market snapshots for specific segments.
  • The Growth Environment section explores market segmentation and the overall growth environment for the next-generation diagnostics market.

Trinity Biotech Announces Q1 2023 Financial Results

Retrieved on: 
Donnerstag, Juli 6, 2023
Clinical chemistry, Total, Total addressable market, AACC, Diabetes, HIV, Diagnosis of HIV/AIDS, Tams, Sale, American Association for Clinical Chemistry, Capital, World Health Organization, Units of paper quantity, Growth, FDA, Calibration, Glycated hemoglobin, Pharmaceutical industry, Retail, Video game, Cryptocurrency, Bank

DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended March 31, 2023.

Key Points: 
  • DUBLIN, Ireland, July 06, 2023 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced the Company’s results for the quarter ended March 31, 2023.
  • Partly offsetting these revenue gains are lower revenues from low margin diabetes instrument deliveries, compared to Q1 2022.
  • Diabetes instrument placements were up approximately 17% in Q1, 2023 vs Q4, 2022.
  • Total revenues for Q1, 2023 were $14.8m which compares to $15.7m in Q1, 2022, a decrease of 5.4% and which were broken down as follows: